Enfuvirtide

Enfuvirtide (T-20, marketed as Fuzeon) is a 36-amino acid synthetic peptide that mimics the heptad repeat 2 (HR2) region of the HIV-1 transmembrane glycoprotein gp41. By binding to the HR1 region of gp41 during the conformational change triggered by CD4/co-receptor engagement, enfuvirtide prevents formation of the six-helix bundle structure required for viral-host membrane fusion, thereby blocking HIV-1 entry into target cells.

Overview

Enfuvirtide emerged from pioneering work by Carl Wild and Tom Matthews at Duke University in the early 1990s, who identified that synthetic peptides corresponding to the C-terminal heptad repeat (HR2) of HIV-1 gp41 could potently inhibit HIV-1 infection in vitro (Wild et al., 1994). The peptide exploits a critical vulnerability in the HIV entry mechanism: after the viral envelope glycoprotein gp120 binds CD4 and a co-receptor (CCR5 or CXCR4), gp41 undergoes a dramatic conformational rearrangement exposing its HR1 coiled-coil trimer. Enfuvirtide binds this transient HR1 intermediate, competitively blocking the interaction between HR1 and HR2 that would normally drive six-helix bundle formation and membrane fusion.

The development of enfuvirtide by Trimeris (later acquired by Roche) represented a proof-of-concept that viral entry could be therapeutically targeted with peptide drugs. Its clinical utility, however, has been constrained by the requirement for twice-daily subcutaneous injections, significant injection site reactions, high manufacturing cost, and the emergence of resistance mutations in the gp41 HR1 domain. Enfuvirtide is therefore reserved primarily for heavily treatment-experienced patients in salvage regimens where other active agents are limited.

Mechanism of Action

Enfuvirtide's mechanism targets the HIV-1 entry process at the membrane fusion step:

• HR1 binding: After gp120 engages CD4 and a co-receptor, gp41 extends its N-terminal fusion peptide toward the host cell membrane and exposes the HR1 coiled-coil trimer. Enfuvirtide binds this HR1 trimer in a dominant-negative fashion, mimicking the endogenous HR2 domain and preventing the native HR1-HR2 interaction (Chan et al., 1997).
• Six-helix bundle inhibition: The formation of the thermostable six-helix bundle (6-HB), in which three HR2 helices pack into the grooves of the HR1 trimer, is the energy source driving membrane fusion. By occupying the HR2-binding groove on HR1, enfuvirtide arrests this process at a pre-fusion intermediate state (Weissenhorn et al., 1997).
• Entry-stage specificity: Unlike reverse transcriptase or protease inhibitors, enfuvirtide acts extracellularly at the viral entry step, before the viral genome enters the host cell. This provides a mechanistically distinct target for combination therapy (Kilby et al., 1998).
• Strain specificity: Enfuvirtide is primarily active against HIV-1; it has limited activity against HIV-2 due to sequence divergence in the gp41 HR1 domain.

Reconstitution Calculator

Research

Safety Profile

Enfuvirtide's safety profile is well characterized from clinical trials and extensive post-marketing experience:

• Injection site reactions (ISRs): Occur in ~98% of patients; pain, induration, erythema, nodules, and pruritus at injection sites. ISRs are the most common reason for discontinuation. Rotating injection sites and proper technique reduce severity (Ball et al., 2003).
• Hypersensitivity: Rare (<1%) systemic hypersensitivity reactions including rash, fever, nausea, rigors, and hypotension; enfuvirtide should be discontinued and not rechallenge.
• Bacterial pneumonia: A higher rate of bacterial pneumonia was observed in enfuvirtide arms of TORO trials (4.68 vs 0.61 events per 100 patient-years); causal relationship uncertain.
• Eosinophilia: Observed in some patients; generally asymptomatic.
• Immune reconstitution: As with all effective antiretrovirals, immune reconstitution inflammatory syndrome (IRIS) may occur in patients with profound immunosuppression.

Pharmacokinetic Profile